Bevasiranib
- Generic Name
- Bevasiranib
- Drug Type
- Biotech
- CAS Number
- 959961-96-7
- Unique Ingredient Identifier
- DGN36694W4
- Background
Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
- Indication
Investigated for use/treatment in macular degeneration and diabetic retinopathy.
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00722384
- Locations
- 🇺🇸
OPKO site, Morristown, New Jersey, United States
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
- Conditions
- Age Related Macular Degeneration
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- OPKO Health, Inc.
- Registration Number
- NCT00557791
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT00499590
- Locations
- 🇺🇸
Retina Institute of California (site 207), Pasadena, California, United States
🇺🇸Miramar Eye Specialists Medical Group (site 245), Ventura, California, United States
🇺🇸Florida Eye Microsurgical Institute, Inc. (site 217), Boynton Beach, Florida, United States
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00306904
- Locations
- 🇺🇸
Retina Associates of Cleveland, Beechwood, Ohio, United States
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00259753
- Locations
- 🇺🇸
Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States
🇺🇸Retina-Vitreous Consultants, Livingston, New Jersey, United States
🇺🇸Vitreoretinal Consultants Houston TX, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.